Agilent Technologies, Inc. (NYSE:A) Shares Sold by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC decreased its stake in Agilent Technologies, Inc. (NYSE:A) by 31.7% during the 2nd quarter, Holdings Channel reports. The firm owned 229,189 shares of the medical research company’s stock after selling 106,418 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Agilent Technologies were worth $29,710,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Quantbot Technologies LP acquired a new stake in shares of Agilent Technologies in the first quarter valued at about $938,000. Cetera Investment Advisers grew its position in shares of Agilent Technologies by 953.3% in the first quarter. Cetera Investment Advisers now owns 32,694 shares of the medical research company’s stock valued at $4,757,000 after purchasing an additional 29,590 shares during the period. UBS Group AG lifted its stake in shares of Agilent Technologies by 84.5% in the fourth quarter. UBS Group AG now owns 325,695 shares of the medical research company’s stock worth $45,281,000 after buying an additional 149,159 shares in the last quarter. TD Asset Management Inc lifted its stake in shares of Agilent Technologies by 27.1% in the fourth quarter. TD Asset Management Inc now owns 1,609,420 shares of the medical research company’s stock worth $223,758,000 after buying an additional 343,175 shares in the last quarter. Finally, iA Global Asset Management Inc. lifted its stake in shares of Agilent Technologies by 26.2% in the first quarter. iA Global Asset Management Inc. now owns 21,770 shares of the medical research company’s stock worth $3,168,000 after buying an additional 4,523 shares in the last quarter. Institutional investors and hedge funds own 87.42% of the company’s stock.

Agilent Technologies Price Performance

Agilent Technologies stock opened at $141.07 on Wednesday. The company’s 50 day simple moving average is $134.34 and its 200-day simple moving average is $138.65. The company has a market capitalization of $41.16 billion, a price-to-earnings ratio of 33.35, a price-to-earnings-growth ratio of 4.86 and a beta of 1.05. Agilent Technologies, Inc. has a 1 year low of $96.80 and a 1 year high of $155.35. The company has a debt-to-equity ratio of 0.34, a quick ratio of 1.64 and a current ratio of 2.15.

Agilent Technologies (NYSE:A) last released its quarterly earnings results on Wednesday, August 21st. The medical research company reported $1.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.26 by $0.06. The business had revenue of $1.58 billion for the quarter, compared to the consensus estimate of $1.56 billion. Agilent Technologies had a net margin of 18.84% and a return on equity of 26.25%. The business’s revenue was down 5.6% on a year-over-year basis. During the same period in the previous year, the firm earned $1.43 EPS. As a group, equities research analysts expect that Agilent Technologies, Inc. will post 5.24 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on A. Barclays raised their price target on shares of Agilent Technologies from $125.00 to $135.00 and gave the stock an “underweight” rating in a research note on Friday, August 23rd. Robert W. Baird decreased their price target on shares of Agilent Technologies from $147.00 to $136.00 and set an “outperform” rating on the stock in a research note on Thursday, May 30th. Wolfe Research downgraded shares of Agilent Technologies from an “outperform” rating to a “peer perform” rating in a research note on Thursday, June 27th. Evercore ISI raised their price target on shares of Agilent Technologies from $130.00 to $135.00 and gave the stock an “in-line” rating in a research note on Thursday, August 22nd. Finally, Bank of America raised their price target on shares of Agilent Technologies from $140.00 to $147.00 and gave the stock a “neutral” rating in a research note on Thursday, August 22nd. One analyst has rated the stock with a sell rating, six have assigned a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $141.60.

Insider Activity

In other news, CEO Padraig Mcdonnell sold 1,958 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $130.00, for a total value of $254,540.00. Following the sale, the chief executive officer now directly owns 25,185 shares of the company’s stock, valued at approximately $3,274,050. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, CEO Padraig Mcdonnell sold 1,958 shares of Agilent Technologies stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $130.00, for a total value of $254,540.00. Following the completion of the transaction, the chief executive officer now owns 25,185 shares in the company, valued at $3,274,050. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Dominique Grau sold 15,000 shares of Agilent Technologies stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $133.28, for a total transaction of $1,999,200.00. Following the completion of the transaction, the senior vice president now owns 49,486 shares of the company’s stock, valued at approximately $6,595,494.08. The disclosure for this sale can be found here. In the last three months, insiders have sold 20,874 shares of company stock valued at $2,811,770. Company insiders own 0.33% of the company’s stock.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.